Findings

What do systematic reviews say?

82 questions · 90 findings · 10 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 15 · 16.7%GRADE not reported 4 · 4.4%Very low 14 · 15.6%Low 39 · 43.3%Moderate 16 · 17.8%High 2 · 2.2%

Tacrolimus 0.1% vs pimecrolimus 1%

Physician's assessment of global response of improvement, clear or excellent ‐ 6 weeks · people with atopic dermatitis

Tacrolimus 0.1% probably leads to higher physician's assessment of global response of improvement, clear or… compared with pimecrolimus 1% (moderate certainty).

1 finding from 1 review

Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
RR 1.8 [1.34, 2.42]
2 studies · 506 participants
Moderate

Tacrolimus 0.1% vs pimecrolimus 1%

Adverse effects ‐ 6 weeks · people with atopic dermatitis

It is very uncertain whether tacrolimus 0.1% changes adverse effects ‐ 6 weeks compared with pimecrolimus 1% (very low certainty).

1 finding from 1 review

Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
RR 0.89 [0.47, 1.71]
2 studies · 506 participants
Very low

Tacrolimus 0.03% vs pimecrolimus 1%

Physician's assessment of global response of improvement · people with atopic dermatitis

Tacrolimus 0.03% may leads to higher physician's assessment of global response of improvement compared with pimecrolimus 1% (low certainty).

1 finding from 1 review

Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
RR 1.42 [1.02, 1.98]
1 study · 139 participants
Low

Tacrolimus 0.03% vs pimecrolimus 1%

Adverse effects ‐ application site reaction · people with atopic dermatitis

Tacrolimus 0.03% showed no clear difference in adverse effects ‐ application site reaction compared with pimecrolimus 1% (low certainty).

1 finding from 1 review

Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
RR 1.07 [0.6, 1.91]
1 study · 141 participants
Low

Tacrolimus 0.03% vs pimecrolimus 1%

Adverse effects ‐ burning · people with atopic dermatitis

Tacrolimus 0.03% showed no clear difference in adverse effects ‐ burning compared with pimecrolimus 1% (low certainty).

1 finding from 1 review

Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
RR 0.87 [0.43, 1.75]
1 study · 141 participants
Low

Tacrolimus 0.03% vs pimecrolimus 1%

Adverse effects ‐ itching · people with atopic dermatitis

Tacrolimus 0.03% showed no clear difference in adverse effects ‐ itching compared with pimecrolimus 1% (low certainty).

1 finding from 1 review

Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
RR 2.37 [0.96, 5.81]
1 study · 141 participants
Low

Tacrolimus 0.03% vs pimecrolimus 1%

Adverse effects ‐ erythema · people with atopic dermatitis

Tacrolimus 0.03% showed no clear difference in adverse effects ‐ erythema compared with pimecrolimus 1% (low certainty).

1 finding from 1 review

Topical tacrolimus for atopic dermatitis 2015 · Cochrane Headline outcomes only
RR 2.2 [0.89, 5.46]
1 study · 141 participants
Low

Tacrolimus 0.1% cream vs placebo

Clearing or excellent improvement · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.1% cream vs placebo

At least 50% reduction in erythema · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.1% cream vs placebo

Quality of life measure · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.1% cream vs placebo

Relapse · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.1% cream vs placebo

Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 14 participants
Moderate

Tacrolimus 0.1% vs Topical clobetasol propionate 0.05% ointment

Pain reduction (VAS 0-10) · People with erosive oral lichen planus

Topical tacrolimus 0.1% ointment showed no clear difference in pain reduction (VAS 0-10) compared with topical clobetasol propionate 0.05% ointment; GRADE not reported.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
MD -0.64 [-1.91, 0.63]
1 study · 29 participants
GRADE not reported

Tacrolimus 0.1% vs Topical clobetasol propionate 0.05% ointment

Side effects · People with erosive oral lichen planus

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
Table 3 (Side-effects). Radfar 2008: burning sensation with topical tacrolimus; transient burning within the first 2 weeks resulted in withdrawal of therapy in 1 participant.
1 study · 29 participants
GRADE not reported

Tacrolimus 0.1% vs Topical clobetasol propionate 0.05% ointment

Reduction in target/mean lesion size · People with erosive oral lichen planus

Topical tacrolimus 0.1% ointment showed no clear difference in reduction in target/mean lesion size compared with topical clobetasol propionate 0.05% ointment; GRADE not reported.

1 finding from 1 review

Interventions for erosive lichen planus affecting mucosal sites 2012 · Cochrane All outcomes
MD 0.00 [-1.09, 1.10]
1 study · 29 participants
GRADE not reported

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Partial renal remission · Patients with proliferative lupus nephritis

Mycophenolate mofetil (MMF) + tacrolimus (TAC) showed no clear difference in partial renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1 [0.78, 1.28]
2 studies · 402 participants
Low

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Stable kidney function · Patients with proliferative lupus nephritis

Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher stable kidney function compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 1.78 [1.4, 2.26]
2 studies · 402 participants
Low

Mycophenolate mofetil (MMF) + tacrolimus (TAC) vs IV cyclophosphamide

Complete renal remission · Patients with proliferative lupus nephritis

Mycophenolate mofetil (MMF) + tacrolimus (TAC) may leads to higher complete renal remission compared with IV cyclophosphamide (CPA) (low certainty).

1 finding from 1 review

Immunosuppressive treatment for proliferative lupus nephritis 2018 · Cochrane Headline outcomes only
RR 2.38 [1.07, 5.3]
2 studies · 402 participants
Low

Tacrolimus 0.1% vs mometasone furoate ointment

Primary: investigator‐rated good/excellent control of symptoms · people with moderate to severe chronic relapsing dyshidrotic eczema on hands

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tacrolimus 0.1% vs mometasone furoate ointment

Primary: participant‐rated good/excellent control of symptoms Not measured · people with moderate to severe chronic relapsing dyshidrotic eczema on hands

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hand eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found